Chloral Hydrate and Other Drugs Used in Sedating Young Children: a Survey of American Academy of Pedodontics Diplomates

Total Page:16

File Type:pdf, Size:1020Kb

Chloral Hydrate and Other Drugs Used in Sedating Young Children: a Survey of American Academy of Pedodontics Diplomates PEDIATRIC DENTISTRY/Copyright © ~983 by The American Academyof Pedodontics/Vol. 5, No. 4 Chloral hydrate and other drugs used in sedating young children: a survey of American Academy of Pedodontics Diplomates William K. Duncan, DDS, MEd Ronald J. Pruhs, DDS, MS Mahmoud H. Ashrafi, DMD, MS A. Charles Post, DDS Abstract side effects. It can be used alone or as a comedication A survey of 325 American Board of Pedodontics agent. Recommendeddosage is 50 mg/kg but no more Diplomates was conducted to determine the use of than two grams in one dose. Chloral hydrate generally chloral hydrate and other sedative medications in is recommended over the barbiturates because of its treating young, uncooperative children needing relative safety; it does not have the same potential for extensive operative procedures. Seventy-one per cent respiratory depression with hypnotic doses. of the respondents returned usable surveys. Seventy- Various degrees of success with chloral hydrate have eight per cent of the Diplomates indicated they use been reported. Anderson2, using empirical methods, sedative agents for these patients. However, the reported excellent results in 280 children. In his study, results of the survey show a lack of consensus among patients selected were unmanageableor needed extensive pedodontists regarding the selection and dosage of restorative work. sedative drugs. More recently, Smith3 compared the effectiveness of chloral hydrate to a placebo in handicapped children. He In recent years, faculty and dental residents in the found no significant improvement in behavior using a Advanced Training Program in Pedodontics of Marquette dosage nomogram of 500-1,500 mg depending on body weight. His youngest patient was four years, three University and MilwaukeeChildren’s Hospital have been 4 successfully treating young, uncooperative children months of age. Barr and coworkers found no signifi- needing extensive operative procedures. Chloral hydrate, cant improvement in behavior with a chloral hydrate alone or as a comedication with other drugs, has been dosage schedule of 40 mg/kg. 5 used as a hypnotic sedative. Tobias and coworkers reported the effectiveness of Before starting a clinical research project on the pro- chloral hydrate in combination with hydroxyzine cedure, the authors wanted more information on the use pamoate on 39 children aged 1.75-10.5 years of age with of sedatives in current pedodontic practices. A survey of a meanage of 3.9 years. The dosage schedule was either American Board of Pedodontics Diplomates was con- 1,0.00 mg or 1,500 mg of chloral hydrate given one hour ducted to determine the extent of chloral hydrate use in preoperatively and 50 mg of hydroxyzine pamoate given pediatric dentistry, comedications commonlyused with the evening before, one hour preoperatively and in chloral hydrate, and other medications used for sedating ~elected cases between the time the child awakened and these children. one hour before the appointment. The average dosage of chloral hydrate was 75 mg/kg with a range of 36-130 Literature Review mg/kg. This dosage schedule is higher than those used A review of the literature shows three major categories in the other studies and would be expected to produce of sedative agents plus nitrous oxide/oxygen. moreof a hypnotic than a sedative effect in patients. King and Berlocher 6 recommendeda dosage of 750-1,250 mg Hypnotics or Sedative Hypnotics of chloral hydrate for the patient between 24 and 25 This category produces sedative effects, allaying anx- pounds. iety through depression of the sensory cortex. Medica- Harris7 stated that the barbiturates sedate quickly, tions commonlyused in this category include chloral have a high frequency of success, and a low frequency hydrate and the short-acting barbiturates, secobarbital, of side effects. Dudley8 recommendedoral dosages of and pentobarbital. Sire1 stated that chloral hydrate is 1.5-2.0 mg/lb of pentobarbital and suggested that den- reasonably fast acting, has a high safety factor, and few tists often prescribe insufficient dosage. 252 SEDATION OF CHILDREN -- AAP DIPLOMATE SURVEY: Duncan et aL Anti-anxiety or Psychosedation Agents reported excellent results using meperidine in combina- This group of drugs produces a calming or quiescent tion with promethazine and chlorpromazine, an anti- effect without loss of consciousness. Hydroxyzine,in the anxiety agent. Most of their subjects were three years of form of Atarax~ or Vistaril b is a popular medication in age or younger. They used intramuscular administration. this category. In addition to being sedative, the drug is Alphaprodine HCI is pharmacologically similar to antihistaminic, antispasmodic, antiemetic, and slightly morphine and meperidine except that onset is rapid and anticholinergic. Wright and McAulay9, in a 1973 survey the duration of action is short. It usually is used as a co- of 812 pedodontists, reported that whena single drug was medication,~7 most often with promethazine. selected for sedation, hydroxyzine was used most often. Alphaprodine HCI usually is administered via sub- Kopel:° reported its use as a sole premedicating agent mucosalinjection. The literature recently has recommend- and recommendedadministration of divided doses. He ed against intramuscular injection because absorption is also suggested its use in comedication with meperidine, too unpredictable,~ Recent literature also stresses safe- chloral hydrate, and nitrous oxide/oxygen ty precautions with the use of alphaprodine HCI.~3A9"22 psychosedation. Recommendationsinclude continuous oxygen administra- Diazepam(Valium) c is another popular sedative agent tion, coadministration of an antagonist, mechanical in the anti-anxiety group. It affects the limbic system, monitoring of blood pressure and heart rate, and precor- altering6 the experience and transmission of emotions. dial stethoscope monitoring. Most people receiving diazepam experience an amnesic effect. 11 Hargreaves12 recommendedoral administration Methods and Materials and divided doses. American Academy of Pedodontics Diplomates were Promethazine (Phenargan), d commonlyprescribed for chosen as the survey population. This decision was bas- its antihistiminic properties, also produces a state of ed on a survey in 1980 from which it was concluded that quiescence. Musselmanand McClure13 stated that used future studies of pedondontic procedures in use could be alone it is not very effective as a sedating agent, but that determined by polling the Diplomates (thus having an it can be used for a child who demonstrates minor ap- economical and valid alternative to conducting a survey prehension. However,it generally is used as a comedica- of23 more than 1,700 Academy members). tion with other drugs. Robbins14 used promethazine in The survey was conducted in October, 1981. Of the comedication with chloral hydrate and found less fre- 325 questionnaires sent, 237 (73%) of the Diplomates quent stomach upset than with chloral hydrate alone. responded with 168 (71%) of the responses usable. Promethazine commonly is used in comedication with The objectives of the survey were to determine: meperidine because of its additive sedative effect and to 1. Howmany pedodontists used sedative agents to control15,16 nausea. treat young, uncooperative patients needing exten- sive work Synthetic Narcotic Analgesics 2. Howmany pedodontists used chloral hydrate alone This third major group of premedication agents reduces or in combination to treat this group of patients acute pain, decreases apprehension and provides a 3. What dosages of chloral hydrate and other drugs sedative effect. Thesedative action of the drugs is a result (if used in comedications) were being administered of effects on the cerebrum. However,they also affect the 4. What other sedatives were being used alone or as medulla and can cause severe respiratory depression. comedications and their dosages. A national survey of American Society of Dentistry for Children membersin 1980 found that the most com- Results mon method of sedating children in dentistry was with Most of the Diplomates (75 %) responded that they use narcotic sedation. ~7 The narcotic agents most common- sedative agents for young children needing extensive ly used were meperidine (Demerol)e and alphaprodine operative procedures; 22%responded that they do not HCI (Nisentil). f Wright and McAulay9 reported that use sedation. A few respondents stated that if the child 35 % of pedodontists surveyed used meperidine and pro- could not be managed with traditional (nonphar- methazine as comedications. macological) techniques, general anesthesia in a hospital Musselman and McClure~3 recommended meperidine was their alternative means of management. for children younger than eight years of age who ex- Chloral hydrate is used alone or as a comedication by hibited~ overt disruptive behavior. Myers and Shoaf 62 %of the Diplomatessedating young children. It should be noted that this does not meanthey use it exclusively. aRoerig,a Divisionof Pfizer Pharmaceuticals;New York, N.Y. Several respondents who indicated they use chloral bpfizerLaboratories Division, Pfizer, Inc.; NewYork, N.Y. hydrate alone or as part of a comedication also listed CRocheLaboratories; Nutley, N.J. dWyethLaboratories; Philadelphia, Pa. other sedative agents in response to a further question eWinthropLaboratories; New York, N.Y. concerning the use of other drugs. fRocheLaboratories; Nutley, N.J. The responses were quite diverse in choice of drug and PEDIATRICDENTISTRY: December
Recommended publications
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
    [Show full text]
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • Medication Guide Sedative-Hypnotic Capsules
    MEDICATION GUIDE SEDATIVE-HYPNOTIC CAPSULES C-II SECONAL SODIUM® CII (secobarbital sodium) CAPSULES, USP Rx only Read this Medication Guide before you start taking a SEDATIVE-HYPNOTIC and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. You and your doctor should talk about the SEDATIVE-HYPNOTIC when you start taking it and at regular checkups. What is the most important information I should know about SEDATIVE-HYPNOTICS? After taking a SEDATIVE-HYPNOTIC, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with a SEDATIVE-HYPNOTIC. Reported activities include: • driving a car ("sleep-driving") • making and eating food • talking on the phone • having sex • sleep-walking Important: 1. Take SEDATIVE-HYPNOTICS exactly as prescribed • Do not take more SEDATIVE-HYPNOTICS than prescribed. • Take the SEDATIVE-HYPNOTIC right before you get in bed, not sooner. 2. Do not take SEDATIVE-HYPNOTICS if you: • drink alcohol • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take SEDATIVE-HYPNOTICS with your other medicines • cannot get a full night's sleep 3. Call your doctor right away if you find out that you have done any of the above activities after taking the SEDATIVE-HYPNOTIC.
    [Show full text]
  • Toxicological Review of Chloral Hydrate (CAS No. 302-17-0) (PDF)
    EPA/635/R-00/006 TOXICOLOGICAL REVIEW OF CHLORAL HYDRATE (CAS No. 302-17-0) In Support of Summary Information on the Integrated Risk Information System (IRIS) August 2000 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document may undergo revisions in the future. The most up-to-date version will be made available electronically via the IRIS Home Page at http://www.epa.gov/iris. ii CONTENTS—TOXICOLOGICAL REVIEW for CHLORAL HYDRATE (CAS No. 302-17-0) FOREWORD .................................................................v AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................ vi 1. INTRODUCTION ..........................................................1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS ..... 2 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS ............................3 4. HAZARD IDENTIFICATION ................................................6 4.1. STUDIES IN HUMANS - EPIDEMIOLOGY AND CASE REPORTS .................................................6 4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS ................................8 4.2.1. Oral ..........................................................8 4.2.2. Inhalation .....................................................12 4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES ..........................13
    [Show full text]
  • Chloral Hydrate and Paraldehyde As Drugs of Addiction
    Sept., 1932J CHLORAL HYDRATE DRUG HABIT : CHOPRA & SINGH CHOPRA 481 certain parts of the Punjab. This is not the outcome of the use of the drug in the treatment Original Articles of insomnia, but is due to entirely different causes. Until a few years ago in that province potable country-made spirits were allowed to CHLORAL HYDRATE AND PARALDE' be sold to retail dealers in bulk and the vendors HYDE AS DRUGS OF ADDICTION bottled the liquor themselves. Some of these ingenious people conceived the idea of diluting R. N. m.d. By CHOPRA, m.a., (Cantab.) the spirit and adding small quantities of chloral I.M.S. LIEUTENANT-COLONEL, hydrate to make up for the loss in its potency and which would result from dilution. The know- GURBAKHSH SINGH CHOPRA, m.b., b.s. ledge that the drug had hypnotic and narcotic was obtained from the (Drug Addiction Inquiry, Indian Research Fund effects undoubtedly Association) medical profession and compounders work- in It was further learnt that Series No. 15 ing dispensaries. the effects chloral hydrate in many Chloral produced by hydrate and paraldehyde belong to resemble those by alcohol, the of ways produced group drugs known as soporifics or especially when the latter is taken in large The chief use of hypnotics. this class of drugs quantities. When the two articles are taken is in the treatment of one insomnia, of the together they act in a manner synergistic to worst evils of modern times from which man- each other and in this way the effect of either kind can suffer.
    [Show full text]
  • Additional Requested Drugs
    PART 1 PART PATIENT PRESCRIBED MEDICATIONS: o ACTIQ o DESIPRAMINE o HYDROCODONE o MORPHINE o ROXICODONE o ADDERALL o DIAZEPAM* o HYDROMORPHONE o MS CONTIN o SOMA o ALPRAZOLAM* o DILAUDID o IMIPRAMINE o NEURONTIN o SUBOXONE o AMBIEN o DURAGESIC o KADIAN o NORCO o TEMAZEPAM o AMITRIPTYLINE o ELAVIL o KETAMINE o NORTRIPTYLINE o TRAMADOL* o ATIVAN o EMBEDA o KLONOPIN o NUCYNTA o TYLENOL #3 o AVINZA o ENDOCET o LORAZEPAM o OPANA o ULTRAM o BUPRENEX o FENTANYL* o LORTAB o OXYCODONE o VALIUM o BUPRENORPHINE o FIORICET o LORCET o OXYCONTIN o VICODIN o BUTRANS o GABAPENTIN o LYRICA o PERCOCET o XANAX o CLONAZEPAM* o GRALISE o METHADONE o RESTORIL TO RE-ORDER CALL RITE-PRINT 718/384-4288 RITE-PRINT CALL TO RE-ORDER ALLIANCE DRUG PANEL (SEE BELOW) o ALCOHOL o BARBITURATES o ILLICITS o MUSCLE RELAXANTS o OPIODS (SYN) ETHANOL PHENOBARBITAL 6-MAM (HEROIN)* CARISPRODOL FENTANYL* BUTABARBITAL a-PVP MEPROBAMATE MEPERIDINE o AMPHETAMINES SECOBARBITAL BENZOYLECGONINE NALOXONE AMPHETAMINE PENTOBARBITAL LSD o OPIODS (NATURAL) METHADONE* METHAMPHETAMINE BUTALBITAL MDA CODEINE METHYLPHENEDATE MDEA MORPHINE o NON-OPIOID o BENZODIAZEPINES MDMA ANALGESICS o OPIODS (SEMI-SYN) o ANTICONVULSIVES ALPRAZOLAM* MDPV TRAMADOL BUPRENORPHINE* GABAPENTIN CLONAZEPAM* MEPHEDRONE TAPENTADOL DIHROCODEINE PREGABALIN DIAZEPAM METHCATHINONE DESOMORPHINE o NON-BENZODIAZEPINE FLUNITRAZEPAM* METHYLONE HYDROCODONE HYPNOTIC o ANTIDEPRESSANTS FLURAZEPAM* PCP HYDROMORPHONE ZOLPIDEM* AMITRIPTYLINE LORAZEPAM THC* OXYCODONE DOXEPIN OXAZEPAM CBD ° OXYMORPHONE o MISCELLANEOUS DRUGS IMIPRIMINE
    [Show full text]
  • Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Common Mechanism S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/21/mol.117.108290.DC1 1521-0111/91/6/620–629$25.00 https://doi.org/10.1124/mol.117.108290 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:620–629, June 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely through a Common Mechanism s Anita Luethy, James D. Boghosian, Rithu Srikantha, and Joseph F. Cotten Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (A.L., J.D.B., and J.F.C.); Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.); Carver College of Medicine, University of Iowa, Iowa City, Iowa (R.S.) Received January 7, 2017; accepted March 20, 2017 Downloaded from ABSTRACT The TWIK-related acid-sensitive potassium channel 3 (TASK-3; hydrate (165% [161–176]) . 2,2-dichloro- . 2-chloro 2,2,2- KCNK9) tandem pore potassium channel function is activated by trifluoroethanol . ethanol. Similarly, carbon tetrabromide (296% halogenated anesthetics through binding at a putative anesthetic- [245–346]), carbon tetrachloride (180% [163–196]), and 1,1,1,3,3,3- binding cavity. To understand the pharmacologic requirements for hexafluoropropanol (200% [194–206]) activate TASK-3, whereas molpharm.aspetjournals.org TASK-3 activation, we studied the concentration–response of the larger carbon tetraiodide and a-chloralose inhibit. Clinical TASK-3 to several anesthetics (isoflurane, desflurane, sevoflurane, agents activate TASK-3 with the following rank order efficacy: halothane, a-chloralose, 2,2,2-trichloroethanol [TCE], and chloral halothane (207% [202–212]) .
    [Show full text]
  • Nembutal [Pentobarbital] Injection and Seconal [Secobarbital] Capsules
    Pharmacy Benefit Coverage Criteria Effective Date .......................................... 12/1/2020 Next Review Date… ................................... 12/1/2021 Coverage Policy Number ................................ P0095 Nembutal [pentobarbital] injection and Seconal [secobarbital] capsules Table of Contents Related Coverage Resources Overview .............................................................. 1 Coverage Policy ................................................... 1 FDA Summary ..................................................... 1 General Background ............................................ 2 References .......................................................... 2 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific
    [Show full text]
  • Oral Chloral Hydrate Compare with Rectal Thiopental in Pediatric Procedural Sedation and Analgesia; a Randomized Clinical Trial
    85 Emergency (2014); 2 (2): 85‐89 ORIGINAL RESEARCH Oral Chloral Hydrate Compare with Rectal Thiopental in Pediatric Procedural Sedation and Analgesia; a Randomized Clinical Trial Reza Azizkhani1, Soheila Kanani1*, Ali Sharifi2, Keihan Golshani1, Babak Masoumi1, Omid Ahmadi1 1. Department of Emergency Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 2. Department of General Surgery, Isfahan University of Medical Sciences, Isfahan, Iran Abstract Introduction: The increasing use of diagnostic imaging in pediatric medicine has resulted in growing need for procedural sedation and analgesia (PSA) to minimize motion artifacts during procedures. The drug of choice in pediatric PSA was not introduced till now. The aim of the present study was comparison of oral chloral hydrate (OCH) and rectal sodium thiopental (RST) in pediatric PSA. Methods: In the present randomized clinical trial, 2‐6 years old pediatrics who referred for performing brain computed tomography scan was enrolled and were randomly divided in to two groups. OCH (50mg/kg) and RST (25mg/kg) were prescribed and a trained nurse recorded the time from drug prescription to receiving the con‐ scious sedation (onset of action), the total time period which the patient has the Ramsay score≥4 (duration of action), and adverse effect of agents. Mann‐Whitney U test and chi‐squared test, and Non‐parametric analysis of covariance (ANCOVA) were used for comparisons. Results: One hundred and forty children were entered to two groups of OCH and RST, randomly. The patients of two groups had similar age, sex, weight, and baseline vital signs except for diastolic blood pressure (p<0.001). The onset of action in OCH and RST groups were 24.5±6.1and 28.7±5.2 minutes, respectively (p<0.001).
    [Show full text]
  • HS 172 R5/13 Briefly Review the Objectives, Content and Activities of This Session
    HS 172 R5/13 Briefly review the objectives, content and activities of this session. Upon successfully completing this session the participant will be able to: • Explain a brief history of the CNS Depressant category of drugs. • Identify common drug names and terms associated with this category. • Identify common methods of administration for this category. • Describe the symptoms, observable signs and other effects associated with this category. CONTENT SEGMENTS LEARNING ACTIVITIES A. Overview of the Category Instructor-Led Presentations B. Possible Effects Instructor Led Demonstrations C. OtdDtifEfftOnset and Duration of Effects RdiAiReading Assignmen ts D. Overdose Signs and Symptoms Video Presentations E. Expected Results of the Evaluation Slide Presentations F. Classification Exemplar HS 172 R5/13 9-2 • Explain the typical time parameters, i.e. onset and duration of effects, associated with this category. • List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. • Correctly answer the “topics for study” questions at the end of this session. HS 172 R5/13 9-3 A. Overview of the Category CNS Depressants Central Nervous System Depressants slow down the operations of the brain. Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.” • Depressants first affect those arareaseas of the brain that control a person’ s conscious, voluntary actions. • Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first. • As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.
    [Show full text]
  • Chloral Hydrate Safety Issues
    December 2016 www.nursingcenter.com Chloral Hydrate Safety Issues Chloral hydrate is a sedative-hypnotic that has been associated with serious adverse events in the pediatric population including dosing errors, over-sedation, and administration of the oral liquid by the intravenous (IV) route. In 2012, commercially available chloral hydrate products were discontinued and taken off the market. However, some ambulatory and hospital pharmacies are compounding an oral suspension of chloral hydrate for pediatric sedation in both inpatient and outpatient settings. Section 503A of the Federal Food, Drug and Cosmetic Act permits pharmacists to compound chloral hydrate to provide patient specific prescriptions in limited quantities. Compounded drugs are not approved by the US Food and Drug Administration (FDA), which means the FDA does not verify the safety or effectiveness of compounded drugs. One study found that compared to the commercial formulation, the compounded drug provided a shorter duration of sedation, more frequent need for an additional sedation agent, and frequent sedation failure. Over the last two years, there have been three reported cases of pediatric chloral hydrate overdoses and one death that occurred in the outpatient setting. Respiratory depression and arrest are two serious adverse events that can occur following chloral hydrate administration. Other risks associated with chloral hydrate use include: Resedation after discharge. Chloral hydrate can result in prolonged sedation or resedation with effects lasting longer than 24 hours in children of all ages, even if they appear to have cleared the sedation prior to discharge. Chloral hydrate is converted to trichloroethanol, which has a half-life of up to 66 hours in neonates, 28-40 hours in infants, 8-12 hours in children, and longer following an overdose.
    [Show full text]